Rainer K Reinscheid

6406866, Jun 18, 2002

Mar 26, 1998

09/048916

David K. Grandy - Portland OR
James R. Bunzow - Portland OR
Olivier Civelli - Irvine CA
Rainer Klaus Reinscheid - Irvine CA
Hans-Peter Nothacker - Irvine CA
Frederick James Monsma - Summit NJ

Oregon Health Sciences University - Portland OR

G01N 3353

435 72, 530300, 530350, 435 691

The present invention relates to a novel mammalian opioid receptor protein and ligands that bind to such proteins. The invention is directed toward the isolation, characterization and pharmacological use of an endogenous ligand that specifically binds to a novel mammalian opioid receptor protein heterologously expressed in mammalian cells. The invention specifically provides the isolated peptide ligand and analogues, derivatives and variants thereof. The invention specifically provides tyrosine substitution variants of the peptide ligand that specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.

6790608, Sep 14, 2004

Feb 9, 2001

09/780576

Olivier Civelli - Irvine CA
Hans-Peter Nothacker - Irvine CA
Zhiwei Wang - Irvine CA
Rainer Reinscheid - Irvine CA

The Regents of the University of California - Oakland CA

C12Q 100

435 4, 435 71, 530350

The present invention provides an isolated nucleic acid molecule containing a nucleotide sequence which encodes an ADP-glucose receptor, and isolated polynucleotides therefrom. Also provided is an isolated ADP-glucose receptor polypeptide, an isolated immunogenic peptide therefrom, and antibodies specific therefor. The invention also provides a method of identifying an ADP-glucose receptor agonist or antagonist, by contacting an ADP-glucose receptor with one or more candidate compounds under conditions suitable for detection of a G-protein coupled signal in response to ADP-glucose, and identifying a candidate compound that alters production of the signal. Further provided is a method of identifying an ADP-glucose receptor ligand, by contacting an ADP-glucose receptor with one or more candidate compounds under conditions suitable for detecting selective binding of ADP-glucose to ADP-glucose receptor, and identifying a candidate compound that selectively binds the ADP-glucose receptor. Also provided are methods of diagnosing or determining susceptibility to ADP-glucose receptor associated conditions, by detecting in a sample from the individual expression of ADP glucose receptor nucleic acid molecules or polypeptides.

20190127419, May 2, 2019

Mar 23, 2017

16/090728

- Research Triangle Park NC, US
- Oakland CA, US
Rainer REINSCHEID - Irvine CA, US
Yanyan ZHANG - Morrisville NC, US
Carla HASSLER - Durham NC, US

C07K 5/068
C07K 5/083
A61P 25/28
C07K 5/087
C07K 5/097
C07K 5/08
C07K 5/103
C07K 5/107
C07K 7/06
A61P 25/18
A61P 25/30
A61P 3/04

Neuropeptide S receptor agonists are provided. The NPS agonists include trimeric, tetrameric, pentameric or hexameric peptidomimetic analogs exhibiting affinity for and activity at the neuropeptide S receptor. The peptidomimetic molecules may be useful in the treatment of disorders, syndromes and conditions mediated by modulation of the neuropeptide S receptor such as substance abuse, narcolepsy, insomnia, obesity, cognitive decline, dementia, Alzheimer's disease, panic disorder, generalized anxiety, PTSD, phobias, schizophrenia and as supportive medication during any kind of cessation program in cognitive behavioral therapy, such as drug addiction, eating disorders and gambling.